These results highlight the new concept that combined Aβ and tau thresholds can predict imminent neurodegeneration as an alternative framework with a high statistical power for testing the effect of disease-modifying therapies on [<sup>18</sup>F]FDG uptake decline over a typical 2-year clinical trial period in individuals with preclinical AD.
A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Middle-aged (9-11 months) transgenic animals (both male and female) displayed mild spatial memory impairments and disrupted cingulate network connectivity measured by resting-state fMRI, even in the absence of hypometabolism (measured with PET [<sup>18</sup>F]FDG) or detectable fibrillary amyloidosis (measured with PET [<sup>18</sup>F]NAV4694).